Advertisement

Topics

LYNPARZA Receives Additional and Broad Approval in the U.S. for Ovarian Cancer

15:36 EDT 17 Aug 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
LYNPARZA’s New Tablet Formulation Approved as Maintenance Treatment for Women With Platinum-Sensitive Recurrent Ovarian Cancer Regardless of BRCA-Mutation Status LYNPARZA Tablets Also Indicated in BRCA-Mutated Ovarian...

Other Sources for this Article

Merck & Co., Inc.
Media:
Pamela Eisele, 267-305-3558
Claire Mulhearn, 908-740-6444
or
Investors:
Teri Loxam, 908-740-1986
Amy Klug, 908-740-1898

NEXT ARTICLE

More From BioPortfolio on "LYNPARZA Receives Additional and Broad Approval in the U.S. for Ovarian Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...